Annual EBITDA
-$152.18 M
-$48.17 M-46.32%
December 31, 2023
Summary
- As of February 8, 2025, KROS annual EBITDA is -$152.18 million, with the most recent change of -$48.17 million (-46.32%) on December 31, 2023.
- During the last 3 years, KROS annual EBITDA has fallen by -$106.93 million (-236.31%).
- KROS annual EBITDA is now -12928.85% below its all-time high of -$1.17 million, reached on December 31, 2018.
Performance
KROS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$58.34 M
-$8.21 M-16.38%
September 30, 2024
Summary
- As of February 8, 2025, KROS quarterly EBITDA is -$58.34 million, with the most recent change of -$8.21 million (-16.38%) on September 30, 2024.
- Over the past year, KROS quarterly EBITDA has dropped by -$29.08 million (-99.40%).
- KROS quarterly EBITDA is now -2523.34% below its all-time high of -$2.22 million, reached on June 30, 2019.
Performance
KROS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$185.94 M
-$15.27 M-8.95%
September 30, 2024
Summary
- As of February 8, 2025, KROS TTM EBITDA is -$185.94 million, with the most recent change of -$15.27 million (-8.95%) on September 30, 2024.
- Over the past year, KROS TTM EBITDA has dropped by -$33.76 million (-22.19%).
- KROS TTM EBITDA is now -6961.94% below its all-time high of -$2.63 million, reached on March 31, 2019.
Performance
KROS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
KROS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.3% | -99.4% | -22.2% |
| 3 y3 years | -236.3% | -188.4% | -199.3% |
| 5 y5 years | -10000.0% | -1571.2% | -1584.4% |
KROS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -170.1% | at low | -1106.4% | at low | -230.0% | at low |
| 5 y | 5-year | -1155.6% | at low | -2068.1% | at low | -1584.4% | at low |
| alltime | all time | <-9999.0% | at low | -2523.3% | at low | -6961.9% | at low |
Keros Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$58.34 M(+16.4%) | -$185.94 M(+8.9%) |
| Jun 2024 | - | -$50.13 M(+4.0%) | -$170.67 M(+5.6%) |
| Mar 2024 | - | -$48.21 M(+64.8%) | -$161.68 M(+6.2%) |
| Dec 2023 | -$152.18 M(+46.3%) | -$29.26 M(-32.1%) | -$152.18 M(-0.2%) |
| Sep 2023 | - | -$43.07 M(+4.7%) | -$152.51 M(+14.8%) |
| Jun 2023 | - | -$41.15 M(+6.3%) | -$132.82 M(+12.0%) |
| Mar 2023 | - | -$38.70 M(+30.8%) | -$118.63 M(+14.1%) |
| Dec 2022 | -$104.00 M(+84.6%) | -$29.59 M(+26.5%) | -$104.00 M(+31.2%) |
| Sep 2022 | - | -$23.38 M(-13.3%) | -$79.25 M(+4.1%) |
| Jun 2022 | - | -$26.96 M(+12.0%) | -$76.10 M(+17.7%) |
| Mar 2022 | - | -$24.07 M(+397.8%) | -$64.67 M(+14.8%) |
| Dec 2021 | -$56.35 M | -$4.84 M(-76.1%) | -$56.35 M(-9.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$20.23 M(+30.3%) | -$62.12 M(+15.4%) |
| Jun 2021 | - | -$15.53 M(-1.4%) | -$53.85 M(+9.9%) |
| Mar 2021 | - | -$15.75 M(+48.6%) | -$49.00 M(+8.3%) |
| Dec 2020 | -$45.25 M(+273.3%) | -$10.60 M(-11.4%) | -$45.25 M(+21.2%) |
| Sep 2020 | - | -$11.96 M(+11.9%) | -$37.34 M(+29.3%) |
| Jun 2020 | - | -$10.69 M(-10.9%) | -$28.87 M(+41.5%) |
| Mar 2020 | - | -$12.00 M(+345.9%) | -$20.41 M(+84.8%) |
| Dec 2019 | -$12.12 M(+937.7%) | -$2.69 M(-22.9%) | -$11.04 M(+32.2%) |
| Sep 2019 | - | -$3.49 M(+57.0%) | -$8.35 M(+71.9%) |
| Jun 2019 | - | -$2.22 M(-15.5%) | -$4.86 M(+84.5%) |
| Mar 2019 | - | -$2.63 M | -$2.63 M |
| Dec 2018 | -$1.17 M | - | - |
FAQ
- What is Keros Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Keros Therapeutics?
- What is Keros Therapeutics annual EBITDA year-on-year change?
- What is Keros Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Keros Therapeutics?
- What is Keros Therapeutics quarterly EBITDA year-on-year change?
- What is Keros Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Keros Therapeutics?
- What is Keros Therapeutics TTM EBITDA year-on-year change?
What is Keros Therapeutics annual EBITDA?
The current annual EBITDA of KROS is -$152.18 M
What is the all time high annual EBITDA for Keros Therapeutics?
Keros Therapeutics all-time high annual EBITDA is -$1.17 M
What is Keros Therapeutics annual EBITDA year-on-year change?
Over the past year, KROS annual EBITDA has changed by -$48.17 M (-46.32%)
What is Keros Therapeutics quarterly EBITDA?
The current quarterly EBITDA of KROS is -$58.34 M
What is the all time high quarterly EBITDA for Keros Therapeutics?
Keros Therapeutics all-time high quarterly EBITDA is -$2.22 M
What is Keros Therapeutics quarterly EBITDA year-on-year change?
Over the past year, KROS quarterly EBITDA has changed by -$29.08 M (-99.40%)
What is Keros Therapeutics TTM EBITDA?
The current TTM EBITDA of KROS is -$185.94 M
What is the all time high TTM EBITDA for Keros Therapeutics?
Keros Therapeutics all-time high TTM EBITDA is -$2.63 M
What is Keros Therapeutics TTM EBITDA year-on-year change?
Over the past year, KROS TTM EBITDA has changed by -$33.76 M (-22.19%)